Transfer of Treasury Shares
Today 11:00
For best results when printing this announcement, please click on link below:https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20261023:nRSW2474Aa&default-theme=true RNS Number : 2474A Venture Life Group PLC 23 October 2026 23 October 2026 VENTURE LIFE GROUP PLC ("Venture Life", "VLG" or the "Group") Transfer of Treasury Shares Venture Life Group PLC (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that today the Company transferred 110,000 ordinary shares of 0.3p each in the Company (“Ordinary Shares”) out of treasury to settle options exercised by an employee in accordance with the Company’s employee share option scheme. Following the transfer, the total number of Ordinary Shares in issue will be 128,860,145, with 10,023,387 Ordinary Shares held in treasury. Therefore, the total number of voting rights will be 118,836,758. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. For further information, please contact: Venture Life Group PLC +44 (0) 1344 578004 Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500 Stephen Keys/George Lawson (Corporate Finance) Michael Johnson (Sales) About Venture Life (www.venture-life.com (http://www.venture-life.com/ ) ) Venture Life is a growing pure-play consumer healthcare company focused on the specific market opportunity of Proactive Healthy Longevity. The company has a core portfolio, its Power Brands, of high growth, high margin products that promote and support consumer's goals of maintaining health and longevity. The Power Brands include Balance Activ in women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health and Her product range supporting the hormonal lifecycle, and the FemiClear products which address a range of common women’s intimate health conditions. These products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels. Venture Life has direct distribution in the UK, Ireland and the USA, supplying products directly to retailer partners and supporting these products in-market. Outside of these territories Venture Life uses international distribution partners to sell its products, with those partners being responsible for the support and distribution of the products in-market This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visitwww.rns.com (http://www.rns.com/ ) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy ) . END TRSGCBDGIUDDGLX Copyright 2019 Regulatory News Service, all rights reserved